Figure 2

I-17 treatment causes aberrant morphology and G1 cell cycle arrest. (A) Epimastigotes non-treated (NT) or treated with 3 µM of I-17 for 4 hours were immunostained for β-tubulin (green) and labeled with DAPI to show the nucleus (N) and kinetoplast (K) (blue). Bars = 5 µM. (B) Percentage of epimastigotes with aberrant morphology after 4 hours treatment with the indicated concentrations of I-17. Boxes are representation of median ± max and min values. **p < 0.01 and ***p < 0.001 were calculated using Mann-Whitney U-test and Student’s T-test by comparing treated with non-treated cells. Flow cytometry of T. cruzi epimastigotes (C) and T. brucei PCF (E) non-treated (NT, black line) or treated for 16 hours with I-17 at 10 µM (red line) stained with propidium iodide before flow cytometry analysis. Cell population in G1 and G2 phases are indicated. Percentage of population from T. cruzi epimastigotes (D) and T. brucei PCF (F) in G1 and G2 cell cycle phases in presence (grey bars) or absence (empty bars) of I-17 are also displayed. The values are means ± standard deviation of triplicate experiments and were analyzed with Student´s t-test with *p < 0.05.